PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|May 17, 2016
AAPS Announces 2016 Award Winners
Author(s)Pharmaceutical Technology Editors
The awards were presented at the AAPS Biotechnology Conference and included awards for ligand binding, innovation in biotechnology, and graduate student symposiums.
Advertisement
On May 16, 2016 Gregory E. Amidon, PhD, president of the American Association of Pharmaceutical Scientists (AAPS), recognized ground-breaking research in the pharmaceutical sciences at the 2016 AAPS Biotechnology Conference. The conference is focused on four distinct themes including, drug discovery, development, engineering, and regulations. The awards presented at AAPS included awards for excellence in ligand-binding assays, innovation in biotechnology, and biotechnology graduate student symposiums. The 2016 award winners include:
AAPS Excellence in Ligand Binding Assays Award
Stephen Harris, Quotient Bioresearch
AAPS Innovation in Biotechnology Awards
Jan Detmers, PhD, Zellkraftwerk
Shawn Fernando, Morphotek, Inc.
Parul Gupta, PhD, Pfizer, Inc.
Piotr Pierog, PhD, Novartis Institutes for BioMedical Research, Inc.
Christopher Shea, Pfizer Inc.
Biotechnology Graduate Student Symposium Awards
Vibhuti Agrahari, University of Missouri Kansas City
Ehab Moussa, Purdue University
John Schardt, University of Maryland, College Park
Kshitij Verma, Texas Tech University, Health Sciences Center
The AAPS Biotechnology Conference took place from May 16-18, 2016 in Boston, Massachusetts. The conference brought together professionals from industry, government, and academia focused on the biotechnology sector of pharmaceutical sciences.
Source: AAPS
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement